SCHEMBL7187626

SCHEMBL7187626

CCC(C)Oc1ccc(PC(=O)c2c(C)cccc2Cl)c(C)c1.[LiH]

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 1/20 0.34
PKM P14618 1/20 0.34
KMT2A Q03164 1/20 0.34
ITGB1 P05556 5/20 0.33
ITGA4 P13612 5/20 0.33
ACACB O00763 3/20 0.33
ITGA2 P17301 1/20 0.33
ITGB7 P26010 1/20 0.33
TRPM4 Q8TD43 1/20 0.32
TYK2 P29597 1/20 0.32
MCL1 Q07820 1/20 0.32
MAPT P10636 3/20 0.32
PYGL P06737 1/20 0.32
TP53 P04637 1/20 0.32
ALDH1A1 P00352 1/20 0.32
ALDH2 P05091 1/20 0.32
MRGPRX4 Q96LA9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180691 0.97 SMN1; SMN2 (0.36) SMN1; SMN2MEN1PKMKMT2AACACB
SCHEMBL7175702 0.92 SMN1; SMN2 (0.38) SMN1; SMN2ACACBMAPTALDH1A1
SCHEMBL7181314 0.91 DHODH (0.34) SMN1; SMN2ITGB1ITGA4ACACBITGA2
SCHEMBL7185567 0.90 HDAC1 (0.35) SMN1; SMN2ITGB1ITGA4ACACBMAPT
Lithium SCHEMBL7181322 0.89 DHODH (0.34) SMN1; SMN2ITGB1ITGA4ACACBITGA2
SCHEMBL7177496 0.89 TYK2 (0.37) SMN1; SMN2MEN1PKMKMT2AITGB1
SCHEMBL7181454 0.86 ACACB (0.36) ITGB1ITGA4ACACBITGA2ITGB7
SCHEMBL7180724 0.85 MCL1 (0.39) SMN1; SMN2MEN1PKMKMT2ATRPM4
SCHEMBL7181996 0.85 DHODH (0.35) SMN1; SMN2ACACBMAPT
Lithium SCHEMBL7180495 0.85 MEN1 (0.35) SMN1; SMN2MEN1PKMKMT2AITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 SMN1; SMN2 2939/4885MEN1 2312/4885PKM 3848/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 SMN1; SMN2 3105/4885MEN1 2263/4885PKM 3933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.